In recent years, cardiovascular disease has become a trend, more and more young people suffer from cardiovascular disease, physical and mental suffering. According to the China Cardiovascular Health and Disease Report 2021, the number of cardiovascular patients in China is as high as 330 million, which is equivalent to one in four Chinese suffering from cardiovascular disease for a long time. Clinically, the mortality rate of cardiovascular disease is also high, with an average of one person dying of cardiovascular disease every ten seconds. Therefore, cardiovascular disease is regarded as the “number one killer” threatening human health in the industry. Common hyperlipidemia, blood viscosity, atherosclerosis, hypertension, and so on are the main factors leading to cardio-cerebrovascular diseases.
Prevention is the key to avoiding cardiovascular disease. However, the common clinical drugs have been a “headache” for patients and pharmacies because of the side effects and high cost of long-term treatment. In this case, Ealing Pharmaceuticals won the “National Science and Technology Progress Award” Tongxinluo capsules into the public’s field of vision.
Behind Tongxinluo Capsules obtaining the highest recommendation rate of Chinese drugstore clerks, it can not be separated from the brand’s strong hard power — driven by the ability to innovate.
Tongxinluo capsule is developed under the guidance of the theory of disease in the treatment of coronary angina pectoris, myocardial infarction, cerebral infarction, diabetic microangiopathy, and other cardiovascular diseases of the patented products, for the national health insurance category A varieties, the national essential drugs catalog varieties, the relevant scientific research has won four national awards. “The research on the treatment of coronary heart disease by Tongxinluo Capsule was awarded the second prize of National Scientific and Technological Progress in 2000; the research on the theory of complex disease and its application was awarded the second prize of National Scientific and Technological Progress in 2006; and the research on the ultramicro pulverization technology and its application of Tongxinluo insect medicine was awarded the second prize of National Scientific and Technological Progress in 2006. Pulverization technology and its application” won the Second Prize of National Technological Invention in 2007; “Construction of Chinese medicine vein theory and its guidance for prevention and treatment of microvascular diseases”, which is one of the main contents of Tongxinluo Capsule series of evidence-based medical research, won the First Prize of National Scientific and Technological Progress in 2019.
Tongxinluo Capsules has carried out a series of basic and clinical evidence-based medical research since it was listed on the market and has accumulated a large amount of evidence-based evidence. Tongxinluo Capsules can protect the microvessels through a variety of mechanisms, the therapeutic effect on cardiovascular and cerebrovascular lesions is remarkable, and is the basic medicine for the treatment of coronary angina pectoris, myocardial infarction, cerebral infarction, diabetes mellitus microangiopathy, and other cardiovascular and cerebral vascular diseases, and its exact lipid-lowering, anti-inflammatory, anticoagulant, vascular endothelial protection, can effectively prevent the occurrence and development of atherosclerosis, for high blood pressure, high blood lipids, diabetes mellitus, smoking, Obesity, and other high-risk patients primary prevention.
Tongxinluo capsules relieve vascular spasms, inhibit the role of stabilizing plaque can be used in the treatment of atherosclerotic plaques, reduce because of plaque rupture caused by infarction, and cerebral infarction incidence, but also protect the microvessels, improve microcirculation perfusion, solve the microvascular protection of the world’s difficult problem of acute infarction, cerebral infarction treatment and prevention of the reoccurrence of diabetes mellitus microvascular complications with precise efficacy, and taking safety, treatment cost It is also safe to take and the cost of treatment is greatly reduced, which reduces the burden of patients and is supported by many patients, and also wins the opportunity for the terminal chain.
At present, Tongxinluo Capsule has been recommended by 24 clinical guidelines and expert consensus, and is listed as a commonly used Chinese medicinal preparation for the treatment of coronary atherosclerotic heart disease in the university textbook of Combined Internal Medicine of Traditional Chinese and Western Medicine (Third Edition for the New Century), which provides authoritative medication bases and guiding suggestions for pharmacy clerks and patients, and is well recognized by both the clerks and the common people.
